Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:TYP)
ASX:TYP
Holding AU:TYP?
Track your performance easily
TYP Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.02 - AU$0.03
Previous CloseAU$0.02
Volume587.84K
Average Volume (3M)1.54M
Market Cap
AU$20.61M
Enterprise ValueAU$21.67M
Total Cash (Recent Filing)AU$4.85M
Total Debt (Recent Filing)AU$3.74M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding62,884,613
10 Day Avg. Volume0
30 Day Avg. Volume1,540,315
Standard Deviation0.15
R-Squared0.29
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Tryptamine Therapeutics News
PremiumCompany Announcements
Strategic Management Shift at Tryptamine Therapeutics
PremiumCompany Announcements
Tryptamine Therapeutics Sets Date for AGM, Advances Clinical Trials
PremiumCompany Announcements
Tryptamine Therapeutics Welcomes New CFO
PremiumCompany Announcements
Tryptamine Advances Psilocin Therapy with Successful TrialPremiumCompany Announcements
Tryptamine Therapeutics’ Psilocybin Trial Shows Promising Results
PremiumCompany Announcements
Tryptamine Therapeutics Halts Trading Ahead of Update
PremiumCompany Announcements
Tryptamine Therapeutics’ ASX Debut and Clinical Advances
PremiumCompany Announcements
Tryptamine Therapeutics Showcases Psilocin TherapyOptions Prices
Currently, No data available
---
Ownership Overview
6.09% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
93.91% Public Companies and
Individual Investors
TYP FAQ
What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.02 and its highest was AU$0.03 in the past 12 months.
What is Tryptamine Therapeutics Limited’s market cap?
Currently, no data Available
When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
Tryptamine Therapeutics Limited’s upcoming earnings report date is Feb 20, 2025 which is in 108 days.
How were Tryptamine Therapeutics Limited’s earnings last quarter?
Tryptamine Therapeutics Limited released its earnings results on Sep 06, 2024. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Tryptamine Therapeutics Limited overvalued?
According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Overvalued.
Does Tryptamine Therapeutics Limited pay dividends?
Tryptamine Therapeutics Limited does not currently pay dividends.
What is Tryptamine Therapeutics Limited’s EPS estimate?
Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics Limited have?
Tryptamine Therapeutics Limited has 1,138,921,900 shares outstanding.
What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
Tryptamine Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:TYP
---
Tryptamine Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.66%
12-Months-Change
Fundamentals
Return on Equity
-241.85%
Trailing 12-Months
Asset Growth
24.42%
Trailing 12-Months
Company Description
Tryptamine Therapeutics Limited
Exopharm Ltd is a biopharmaceutical company operating in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. Its products Plexaris and Exomere are developed using LEAP manufacturing process.
---
Technical Analysis
LBT Innovations Limited
―
Tissue Repair Ltd
―
BCAL Diagnostics Limited
―
Regeneus Ltd.
―
---